Arecor for the Best Solution

Arecor for the best solution Find out more

Arecor for the best solution Market-Solutions/
Better delivery routes for liquid biological therapies Market-Solutions/hospital-home/
Heat-stable vaccines: liquid biologics without refrigeration Market-Solutions/stable-vaccines/
Liquid biologics for emergency use Market-Solutions/stable-liquid-formulations/
Market enabling solutions: labile pipeline biologics Market-Solutions/development-solutions/

Latest News

Arecor spun-out from Unilever Research to pioneer and develop dramatically better delivery forms for proteins & biological therapies.

By applying science of the highest calibre Arecor uncovers new insights in protein chemistry, enabling development of differentiating next generation biologics.

Alan Smith, FRS CBE, Former CSO, Genzyme
The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles.

Bob Mattaliano, Group VP Biologics Development, Genzyme
Arecor has transformed the development paths and delivery options for a wide range of new therapeutic products by working closely with partner companies to employ their suite of rationally-derived stabilisation technologies.

Andy J M Richards, Biotechnology Entrepreneur and Business Angel
Arecor’s biologic stabilisation technology provided the stabilisation breakthrough needed for commercialisation of Oxyzyme and Iodozyme, Archimed's unique wound healing products.

Paul Davis, Chief Scientific Officer, Archimed LLP